Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03394781 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
A Phase 2 study, sponsored by Durect.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03394781: Clinical Trial Phase 2 study, sponsored by Durect.
NCT03394781 is a Phase 2 study that was terminated before completion, run by Durect. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03394781, a Phase 2 study, was terminated before completion, sponsored by Durect.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).
Interventions
- DRUG DUR-928
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 2 |
Why NCT03394781 stopped before completion
NCT03394781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which DUR-928 is the first listed.
NCT03394781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03394781 about?
NCT03394781 is a clinical study titled "A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)". This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).
What is the current status of trial NCT03394781?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-01-22. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT03394781?
The interventions under investigation include: DUR-928 (DRUG).
Who is sponsoring clinical trial NCT03394781?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03394781's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI